FDA OKs Corin’s Unity Knee MC Tibial Insert for ApolloKnee

Corin has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its Unity Knee medial constrained (MC) tibial insert.
 
This latest enhancement provides surgeons with the option to independently stabilize the medial compartment during a standard or robotic-assisted total knee arthroplasty (TKA).
 
The Unity Knee MC tibial insert helps restore native knee kinematics by stabilizing the medial condyle while allowing lateral translation. It’s suitable for use with or without the posterior cruciate ligament (PCL).
 
The insert is manufactured with Corin’s ECiMa bearing technology, a vitamin-E enriched, highly cross-linked polyethylene that offers low wear characteristics, oxidative stability, and enhanced mechanical performance. It’s compatible with ApolloKnee, Corin’s next-gen robotic-assisted surgical platform.
 
ApolloKnee provides an objective, dual compartment, sensing, and tensing balance assessment prior to bone resections, letting surgeons optimize knee function in real-time. 

---

MORE INFO: Corin Debuts its ApolloKnee Platform

---

“Studies have demonstrated that a balanced joint has a greater impact on total knee replacement outcomes than component alignment alone. Combining Unity Knee MC with the robotic soft tissue balancing capabilities of ApolloKnee, a new level of natural joint kinematics and stability can be achieved throughout the range of motion. We believe this will provide patients with a more natural feeling knee,” said Christopher Plaskos, Ph.D., VP, Global Clinical Innovation at Corin.
 
The Unity Knee MC Tibial Insert is exclusively available in the U.S. via limited market release.
 
“With the recent 510(k) clearances of the Unity Knee MC and PS-C Tibial Inserts, we’re expanding the range of solutions for surgeons to achieve personalized dynamic knee balance,” said Jim Pierrepont, Global Franchise Lead at Corin. “These advancements reflect our ability to respond quickly to market needs while delivering high-quality innovations. We’re also anticipating further clearances in the coming months, which will strengthen our implant, Apollo, and CorinConnect digital portfolios. With our agile R&D pipeline, we remain committed to providing differentiated solutions that enhance patient outcomes.”